Emma Link

Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites

Zheng Liu, Jennifer H Martin, Winston Liauw, Sue-Anne Mclachlan, Emma Link, Anetta Matera, Michael Thompson, Michael Jefford, Rod J Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian Campbell, Simone Crowley, Phillip J Beale, Christos S Karapetis, Timothy Price, Mathew E Burge, Michael Michael

Journal article  |  2021  |  EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

BACKGROUND: Body surface area (BSA)-based dosing of irinotecan (IR) does not account for its pharmacokinetic (PK) and pharmacodyna..

Ipilimumab nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab nivolumab in advanced non-clear cell renal cell carcinoma.

Craig Gedye, David William Pook, Laurence Eliot Miles Krieger, Carole A Harris, Jeffrey C Goh, Ganessan Kichenadasse, Howard Gurney, Craig Underhill, Francis Parnis, Anthony M Joshua, Tom Ferguson, Felicia Roncolato, Michelle L Harrison, Stephen Begbie, Michelle Frances Morris, Elizabeth J Hovey, Mathew George, Prashanth Prithviraj, Emma Link, Ian D Davis

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

4565 Background: Immunotherapy targeting PD1 is active across many cancers, but many people are failed by PD1 inhibition alone. U..

Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study

Michael Michael, Winston Liauw, Sue-Anne McLachlan, Emma Link, Annetta Matera, Michael Thompson, Michael Jefford, Rod J Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian G Campbell, Simone Rowley, Phillip J Beale, Christos S Karapetis, Timothy Price, Mathew E Burge

Journal article  |  2021  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

PURPOSE: Irinotecan (IR) displays significant PK/PD variability. This study evaluated functional hepatic imaging (HNI) and extensi..

A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

Boon Hui Chua, Emma Link, Ian Kunkler, Ivo Olivotto, Antonia Helen Westenberg, Timothy Whelan, Guenther Gruber

Conference Proceedings  |  2021  |  CANCER RESEARCH

ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

Nathan Lawrentschuk, Roslyn Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Shakher Ramdave, LihMing Wong, Kim Taubman, SzeTing Lee, Edward Hsiao, Michelle Nottage, Ian Kirkwood, Emma Link, Alan Herschtal, Petra Marusic, Anetta Matera, Amir Iravani, et al.

Conference Proceedings  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Madeleine T King, Emma K Link, Tim J Whelan, Ivo A Olivotto, Ian Kunkler, Antonia Helen Westenberg, Guenther Gruber, Penny Schofield, Boon H Chua

Journal article  |  2020  |  LANCET ONCOLOGY

BACKGROUND: BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boos..

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Ramdave Shakher, Lih-Ming Wong, Kim Taubman, Sze Ting Lee, Edward Hsiao, Paul Roach, Michelle Nottage, Ian Kirkwood, Dickon Hayne, Emma Link, Petra Marusic, et al.

Journal article  |  2020  |  LANCET

BACKGROUND: Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised pro..

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

Andrew James Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, Laura Galleta, Amanda Seegum, Alan Herschtal, Emma Link, Margaret Mary McJannett, Elizabeth Chien Hern Liow, Peter S Grimison, Alison Yan Zhang, Nitya Patanjali, Siobhan Ng, Robert Goodwin, Colin Tang, Colin Chen, Elizabeth J Hovey, George Hruby, Alexander David Guminski, Ian D Davis

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

485 Background: In patients (pts) with muscle invasive bladder (MIBC) suitable for curative definitive chemoradiotherapy (CRT), w..

The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (F-18) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors

Mei Sim Lung, Rodney J Hicks, Nick Pavlakis, Emma Link, Michael Jefford, Benjamin Thomson, David K Wyld, Winston Liauw, Timothy Akhurst, Narmatha Kuru, Michael Michael

Journal article  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

AIMS: This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrin..

International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast

Ivo A Olivotto, Emma Link, Claire Phillips, Timothy J Whelan, Guy Bryant, Ian H Kunkler, A Helen Westenberg, Kash Purohit, Verity Ahern, Peter H Graham, Mohamed Akra, Orla McArdle, Joanna J Ludbrook, Jennifer A Harvey, John H Maduro, Carine Kirkove, Guenther Gruber, Joseph D Martin, Ian D Campbell, Geoff P Delaney, et al.

Journal article  |  2020  |  RADIOTHERAPY AND ONCOLOGY

PURPOSE: To assess the cosmetic impact of breast conserving surgery (BCS), whole breast irradiation (WBI) fractionation and tumour..